ODOwen A. Davis

Owen A. Davis

*This is an algorithmically generated author record based on publicly available information.

Owen A. Davis has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data1 from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy

    by Helen M.R. Robinson, Vera Grinkevich, Jayesh B. Majithiya, Sam E. Mann, Claire McWhirter, Eeson Rajendra, Marco Ranzani, Martin L. Stockley, Paula Costales, Owen A. Davis, et al.

    Supplementary data to support the main figures

  • Open Access

    The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy

    by Helen M.R. Robinson, Vera Grinkevich, Jayesh B. Majithiya, Sam E. Mann, Claire McWhirter, Eeson Rajendra, Marco Ranzani, Martin L. Stockley, Paula Costales, Owen A. Davis, et al.

    Purpose: DNA polymerase theta (Polθ) is the central component of DNA double-strand break repair through microhomology-mediated end joining (MMEJ). Targeting Polθ for cancer therapy has been proposed due to its tumor-selective expression, as well as its role in the survival of homologous recombination–deficient (HRD) cancer cells. Additionally, inhibition of Polθ has been shown to potentiate the effects of DNA damage, such as that caused by poly (ADP-ribose) polymerase (PARP) inhibition. In this study, we present the pharmacologic profile of ART6043, a potent, selective, allosteric, small-molecule inhibitor of the polymerase function of Polθ. Experimental Design: A series of in vitro studies were performed to demonstrate the biochemical and cellular on-target activity of ART6043 in relevant model systems, focusing on combination with PARP inhibitors. Subsequent in vivo studies established a pharmacokinetic/pharmacodynamic/efficacy relationship and explored ART6043’s ability to potentiate the efficacy of PARP inhibitors across a range of cell line-derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse models of HRD tumors. Results: ART6043 inhibits Polθ with low nmol/L potency and specifically abrogates MMEJ in cells. Additionally, ART6043 inhibits the survival of HRD cells and potentiates the efficacy of PARP inhibitors in vitro. Furthermore, ART6043 has excellent pharmaceutical properties, is well tolerated, and induces tumor regressions in combination with PARP inhibitors in vivo in HRD models. Conclusions: The data demonstrate strong potential for ART6043 as an anticancer therapeutic for HRD tumors in combination with PARP inhibitors. Based on this, combination therapy of ART6043 with PARP inhibitor treatment is being tested in an ongoing phase I/IIa clinical trial (NCT05898399).


  • Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1

    by Sam E. Mann, Owen A. Davis, Jörg Bomke, Irina Cornaciu, Elias Elinati, Bruce Follows, Alessandro Galbiati, Lerin Geo, Diego Grande, Catherine Jorand-Lebrun, et al.

    Exonuclease 1 (EXO1) is emerging as a target of interest in oncology due to its involvement in multifaceted DNA metabolic processes, particularly in homologous recombination (HR). Evidence is building that BRCA1-deficient cancers are sensitive to loss of EXO1, suggesting therapeutic potential for treating certain subsets of patients. However, EXO1 remains under-explored, with very few reported inhibitors, and there is a paucity of good quality, potent, and selective pharmacological tools to explore its biology. Here, we describe a metal-chelating fragment screen, which resulted in highly selective, submicromolar EXO1 hits. Our subsequent structure-based design and optimization led to the discovery of ART5537, the first highly potent and selective EXO1 inhibitor. We demonstrate that inhibition of EXO1 leads to potent suppression of HR in cells and that the HR inhibition of ART5537 is driven exclusively by EXO1. Furthermore, we show that ART5537 sensitizes cancer cells to ionizing radiation (IR) and synergizes with PARP inhibitors (PARPi).


  • Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor

    by Sam E. Mann, Julien Lefranc, Omar Alkhatib, Roch Boivin, JörG Bomke, Robert T. Byrne, Carolina P. Cassona, Xiaoling Chen, Irina Cornaciu, Paula Costales, et al.

    Flap endonuclease 1 (FEN1) is a long-standing target of interest in the DNA damage response (DDR) field due to its therapeutic potential in BRCA mutant cancers. To-date there have only been a handful of FEN1 inhibitors reported in the literature, most of which display modest selectivity and/or weak cellular activity. As such, there is a need for more advanced pharmacological tools to probe the biology of FEN1. Here, we report the discovery of MSC778, the first potent, selective, and orally bioavailable FEN1 inhibitor. We describe our metal-chelating fragment screening approach and structure-based optimization to identify MSC778, using structural insights to drive design. Consistent with FEN1 inhibition, MSC778 selectively kills BRCA2-deficient cells and potentiates the activity of PARPi niraparib in vivo to induce tumor stasis in a BRCA2 KO DLD-1 mouse xenograft. Furthermore, we illustrate how development of this approach has the potential for addressing nucleases as a target class.